Axial Spondyloarthritis (Ankylosing Spondylitis)
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V)
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in participants with radiographic axial spondyloarthritis (rad-axSpA) who have never taken biological disease-modifying anti-rheumatic drugs (bDMARDs).
The results of this study are not yet available.
Your participation could last up to 20 months and include 15 visits to the study center
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must be diagnosed with radiographic axial spondyloarthritis (rad-xSpA) with inflammation of the sacroiliac joint or region
Participant must be able to walk
Participants must not have received any prior, or are currently receiving, treatment with biologics, tumor necrosis factor inhibitors or other immunomodulatory agents
Participant must have a history of back pain greater than or equal to 3 months which began at age 45 or younger
Participant must not have received a live vaccine within 12 weeks or received a vaccine with Bacillus Calmette-Guerin (BCG) within the past year
Participant must not have had major surgery within 8 weeks of baseline and will not require surgery during the study
Female participant must not be pregnant or breastfeeding